ImmunoGen earns $10M milestone from Bayer related to ADC technology

ImmunoGen earns $10M milestone from Bayer related to ADC technology

Anetumab ravtansine is an anticancer agent that utilizes ImmunoGen's antibody-drug conjugate (ADC) technology. Bayer is developing the product candidate for the potential treatment of mesothelin-expressing cancers under a 2008 license agreement that …

(Visited 7 times, 1 visits today)
3
Like
Save

Comments

Comments are disabled for this post.